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A substantial subset of patients with T cell acute lymphoblastic leukemia (T-ALL) develops resistance to steroids and 
succumbs to their disease. JDP2 encodes a bZIP protein that has been implicated as a T-ALL oncogene from insertional 
mutagenesis studies in mice, but its role in human T-ALL pathogenesis has remained obscure. Here we show that JDP2 
is aberrantly expressed in a subset of T-ALL patients and is associated with poor survival. JDP2 is required for T-ALL cell 
survival, as its depletion by short hairpin RNA knockdown leads to apoptosis. Mechanistically, JDP2 regulates prosurvival 
signaling through direct transcriptional regulation of MCL1. Furthermore, JDP2 is one of few oncogenes capable of initiating 
T-ALL in transgenic zebrafish. Notably, thymocytes from rag2: jdp2 transgenic zebrafish express high levels of mcl1 and 
demonstrate resistance to steroids in vivo. These studies establish JDP2 as a novel oncogene in high-risk T-ALL and implicate 
overexpression of MCL1 as a mechanism of steroid resistance in JDP2-overexpressing cells.
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Introduction
With the availability of next-generation sequencing technol-
ogy, a large number of recurrently mutated genes have been 
identified that contribute to the molecular pathogenesis of can-
cer, spurring the development of targeted therapies. However, 
such large-scale genomic approaches also identify a significant 
number of “passenger” mutations of uncertain functional rel-
evance and disregard potential oncogenes whose expression is 
dysregulated in the absence of an identifiable genomic lesion. 
A powerful complementary approach to the discovery of novel 
oncogenes and tumor suppressors has been the use of retroviral 
and transposase-based insertional mutagenesis screens (Nusse 
and Varmus, 1982; Callahan, 1996; Collier et al., 2005; Dupuy 
et al., 2005, 2006; Copeland and Jenkins, 2010; McIntyre et al., 
2012). For instance, int-2/fibroblast growth factor-3 (FGF3), an 
oncogene that is recurrently amplified in human breast tumors, 
first came to prominence because of its dysregulation resulting 
from a shared integration site of mouse mammary tumor virus in 
murine models of breast cancer (Nusse and Varmus, 1982; Casey 
et al., 1986; Callahan, 1996). Insertional mutagenesis screens 
have been particularly effective in identifying novel oncogenes 
in T cell acute lymphoblastic leukemia (T-ALL). The first studies 
implicating Notch-1 as a major driver of T-ALL came from inser-
tional mutagenesis screens using Moloney murine leukemia 
virus injected into neonatal mice (Girard et al., 1996). Remark-
ably, the majority of insertions occurred within the HD and PEST 
domains of Notch-1, sites that are hotspots for somatic mutation 
in a high proportion of human T-ALL cases, highlighting the rel-
evance of such approaches to human biology (Girard et al., 1996; 
Hoemann et al., 2000; Weng et al., 2004).
JDP2 is a transcription factor whose expression is recurrently 
up-regulated because of a common integration site in murine 
insertional mutagenesis models of T-ALL, yet its role in the 
human disease has not been investigated (Stewart et al., 2007; 
Rasmussen et al., 2009, 2010). This small bZIP protein contains 
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an N-terminal domain that recruits cofactors, a basic domain 
that binds DNA, and a leucine zipper domain capable of heterod-
imerization with other bZIP proteins, such as c-JUN and DDIT3 
(Aronheim et al., 1997; Weidenfeld-Baranboim et al., 2008). The 
role of JDP2 in cancer is controversial because it can partially 
transform chicken embryonic fibroblasts and accelerate hepa-
tocellular carcinoma in mice, yet it has a tumor-suppressor role 
in human prostate cancer, features that may relate to its ability 
to both activate and repress AP-1 target sites, depending on the 
cellular context and bZIP binding partner (Blazek et al., 2003; 
Heinrich et al., 2004; Bitton-Worms et al., 2010).
Here we show that JDP2 is frequently aberrantly expressed 
in human T-ALL and establish its oncogenic role by demonstrat-
ing that it can initiate T-ALL in transgenic zebrafish. JDP2 over-
expression is associated with a poor outcome in patients and is 
required for survival of human T-ALL cells in vitro. Mechanisti-
cally, JDP2 transcriptional activity promotes cell survival through 
direct activation of the anti-apoptotic MCL1 protein. Finally, we 
show that jdp2 overexpression leads to mcl1 up-regulation and 
steroid resistance in vivo, providing a potential explanation 
for the poor survival of T-ALL patients whose leukemic blasts 
overexpress JDP2.
Results
Jdp2 is a common integration site in murine models of T-ALL
To identify novel human T-ALL oncogenes, we explored the Ret-
rovirus and Transposon Tagged Cancer Gene Database (RTC GD), 
which contains the collated results of insertional mutagenesis 
studies of murine T-ALL (Akagi et al., 2004). The majority of 
recurrent retroviral integration sites were in the vicinity of genes 
with well-recognized roles in T-ALL pathogenesis, including (in 
order of frequency) Myc, Gfi1, Notch1, Myb, Pim1, miR17-92, 
Ccnd3, Zeb2, and Akt1 (Fig. 1 A). Notably, Jdp2, encoding a bZIP 
protein without a reported role in human T-ALL, was the third 
most frequently retrovirally targeted gene, with the majority of 
insertions occurring on a CD2-Myc/Runx2 genetic background, 
suggesting that Jdp2 likely collaborates with these genes in trans-
formation (Stewart et al., 2007). Insertions were clustered either 
within intron 2 or ∼50 kb upstream of the transcription start site 
(TSS), with most oriented antisense to Jdp2 and reported to acti-
vate gene expression (Rasmussen et al., 2009, 2010). Insertions 
in the vicinity of Jdp2 are not limited to retroviral models of 
T-ALL; recent studies of T-ALL initiated by the Sleeping Beauty 
transposon have also identified a shared integration site at the 
Jdp2 promoter and have shown that the inserted transposon 
drives Jdp2 overexpression (van der Weyden et al., 2013). Thus, 
both genome-wide retroviral and transposon insertional experi-
ments implicate Jdp2 as a T-ALL oncogene in mice.
JDP2 expression is associated with early T cell progenitors 
(ETPs)/immature T-ALL and poor outcome
To address whether JDP2 is aberrantly expressed in T-ALL 
patients compared with normal thymocytes, we isolated human 
thymic subsets at various levels of differentiation and per-
formed quantitative RT-PCR (qPCR) for JDP2. A brief wave of 
JDP2 expression was detected at the immature single-positive 
(ISP) and triple-negative stage of thymic maturation but was 
not detected in CD34+CD1a− ETPs or more mature thymocytes. 
In direct comparison, 10 of 34 T-ALL patients expressed JDP2 at 
higher levels than ISP cells (Fig. 1 B). Analysis of published data-
sets showed that the gene was more highly expressed in both 
pediatric and adult T-ALL patients whose leukemic cells had an 
immature/ETP-ALL phenotype (Fig. 1 C; P = 0.006 and P = 0.001, 
respectively), at a stage when JDP2 is not normally expressed 
(Gutierrez et al., 2010; Van Vlierberghe et al., 2013). High lev-
els of JDP2 expression were not obviously associated with other 
specific genetic or cytogenetic lesions (Fig. 1 D; Gutierrez et al., 
2010; Van Vlierberghe et al., 2013). Given previous studies that 
ETP-ALL is associated with a poor outcome (Coustan-Smith et al., 
2009), we stratified patients according to JDP2 expression level 
and analyzed their survival. JDP2-positive patients had an infe-
rior probability of 5-yr overall survival compared with JDP2-neg-
ative patients (40% vs. 74% 5-yr overall survival, respectively, P 
= 0.03; Fig. 1 E), raising the possibility of a direct role for JDP2 
in chemoresistance. In support of this concept, although patient 
numbers were small, JDP2 was a poor prognostic marker within 
the ETP group itself, identifying an ETP+JDP2+ group with a par-
ticularly dismal outcome (Fig. 1 E).
To identify a cell line model to further investigate JDP2 func-
tion, we assessed JDP2 mRNA expression in a panel of >20 human 
T-ALL cell lines. JDP2 was most highly expressed in Loucy cells 
(Fig. 1 F), a cell line with the gene expression signature of ETP-
ALL, which is consistent with data from primary patient samples 
(Van Vlierberghe et al., 2011; Anderson et al., 2014). Furthermore, 
JDP2 was highly expressed at the protein level in a subset of the 
T-ALL cell lines by Western blotting, at levels that correlated with 
mRNA expression levels (Fig. 1 F).
JDP2 is required for the survival of T-ALL cells
To assess whether JDP2 is required for the survival of T-ALL 
cells, we performed shRNA knockdown experiments in Loucy 
and KOPT-K1 cells, the two T-ALL cell lines with the highest 
levels of JDP2 expression. We identified two independent shR-
NAs (shRNA#1 and #2) that efficiently depleted JDP2 protein 
expression, and both shRNAs significantly impaired growth 
of Loucy and KOPT-K1 cells (Fig. S1). The JDP2 shRNAs did not 
demonstrate broad toxicity across a panel of cancer cell lines as 
determined through the Achilles project (Fig. S2 A; Tsherniak 
et al., 2017), nor in DND-41 T-ALL cells that do not express JDP2 
(Fig. S2 B). Importantly, we were able to completely rescue the 
inhibitory effects on cell growth through stable expression of 
a JDP2 transgene containing “wobble” bases at the target site of 
shRNA#2, showing that the effect on cell growth was caused by 
knockdown of JDP2 and not off-target shRNA activities (Fig. S2 
C). To study the effects of JDP2 depletion in more detail, we estab-
lished stable cell line clones expressing a doxycycline-inducible 
JDP2 shRNA#2. shRNA induction led to a dramatic impairment 
of cell growth in both cell lines (Fig. 2 A). This effect was medi-
ated through apoptosis as determined by flow cytometry for TdT-
dUTP nick-end labeling (TUN EL) and annexin V (Fig. 2 B and Fig. 
S3 A), as well as PARP1 cleavage and cleaved caspase-3 (Fig. S3 B). 
Furthermore, the kinetics of the onset of apoptosis corresponded 
with JDP2 protein depletion (Fig. 2 C).
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Figure 1. JDP2 is a common integration site in murine insertional mutagenesis studies of T-ALL and is aberrantly expressed in some patients with 
T-ALL. (A) Number of insertions identified from multiple murine retroviral insertional screens for T-ALL, collated on the RTCG database (Akagi et al., 2004). Gray 
bars are genes not yet implicated in human T-ALL. (B) JDP2 mRNA expression as determined by qPCR from 34 diagnostic adult T-ALL cases from the UKA LL14 
trial (black circles) and directly compared with normal thymic subsets sorted by FACS (blue circles). Thymocyte subsets were pooled from five individual donors 
to reduce intersample variation. qPCR experiments were performed in triplicate from two independent experiments. TN, triple-negative; DP, double-positive; 
SP, single-positive. Data points represent the mean ± standard error of the mean. (C) JDP2 expression as determined by Affymetrix gene expression array data 
for 40 pediatric T-ALL patients treated on the COG P9404 trial, separated according to ETP status (Gutierrez et al., 2010). JDP2 expression as determined by 
Illumina bead-chip array for 53 adult T-ALL patients treated on the ECOG E2993 trial, comparing patients with immature versus cortical/mature phenotypes 
(Van Vlierberghe et al., 2013). P values were calculated using the two-tailed Student’s t test. (D) Heatmap showing Affymetrix gene expression data for T-ALL 
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JDP2 binds to TPA-response element (TRE) sites and can both 
activate and repress its target genes
To gain insight into the transcriptional role of JDP2, we performed 
chromatin immunoprecipitation (ChIP) with massively parallel 
sequencing (ChIP-seq) in Loucy cells. Analysis of favored binding 
motifs identified a significant preference for JDP2 binding at the 
palindromic TRE sequence ATGA[C/G]TCAT (corrected P value 
= 3.5 × 10−20; Fig. 3 A), a sequence previously demonstrated to 
bind JDP2 in functional experiments (Weidenfeld-Baranboim et 
al., 2008; Jolma et al., 2013). Interestingly, there was no enrich-
ment for JDP2 binding to the cAMP response element (CRE) 
sequence ATG ACG TCAT (corrected P value = 1). JDP2 occupied 
both active promoters and enhancers, as illustrated by its cooccu-
pancy with histone H3 lysine 27 acetylation (H3K27ac; Fig. 3 A). 
The fact that JDP2 binding correlates with H3K27Ac modifica-
tion indicates that JDP2 binding is likely affecting the expres-
sion levels of expressed genes. We performed RNA-seq shortly 
after JDP2 knockdown in KOPT-K1 and Loucy cells and, despite 
modest knockdown, detected a similar number of differentially 
up-regulated and down-regulated genes after JDP2 depletion (in 
KOPT-K1, 102 significantly up-regulated and 95 significantly 
down-regulated; in Loucy, 192 significantly up-regulated and 
417 significantly down-regulated; Fig. 3 B). Approximately 25% 
of differentially expressed genes were also bound by JDP2, sug-
gesting these were direct transcriptional targets of JDP2, and that 
JDP2 may participate in complexes that function either as a tran-
scriptional activators or transcriptional repressors of its direct 
target genes (Fig. 3 C).
JDP2 directly regulates MCL1 expression in T-ALL
We postulated that the dramatic and rapid induction of apoptosis 
on knockdown of JDP2 might occur through its ability to directly 
regulate one or more anti-apoptotic genes. To investigate such 
an association in primary T-ALL samples, we performed cor-
relation analysis to identify genes whose expression was most 
closely related to that of JDP2, using expression data from 165 
T-ALL cases in the MILE study (Table S1; Haferlach et al., 2010). 
There was a striking positive correlation between MCL1 mRNA 
expression and that of JDP2 (Fig. 4, A and B; Pearson coefficient 
0.50, P = 6 × 10−12), an association that we were able to validate in 
three independent T-ALL cohorts (Fig. S4).
To address the possibility that JDP2 directly regulates MCL1, 
we analyzed our ChIP-seq data and identified JDP2 binding and 
H3K27ac enrichment at the MCL1 promoter, as well as at a puta-
tive MCL1 enhancer site 34 kb upstream of the gene (Fig. 4 C) that 
resides within the same insulated neighborhood as MCL1 (Hnisz 
et al., 2016). Consistent with a direct regulatory role, knockdown 
of JDP2 in stable cell line clones expressing a doxycycline-in-
ducible JDP2 shRNA#2 was associated with a marked reduction 
of MCL1 mRNA expression (Fig. 4 D), as well as a concomitant 
reduction in MCL1 protein expression, with simultaneous induc-
tion of PARP1 cleavage (Fig. 4 E). Furthermore, when we engi-
neered Loucy and KOPT-K1 cells to stably express MCL1 such 
that it was no longer under the transcriptional control of JDP2, 
the adverse effects on cell viability after JDP2 depletion were sig-
nificantly, albeit partially, rescued (Fig. 4 F). Together, these data 
indicate that JDP2 maintains T-ALL cell survival by up-regulating 
MCL1 through direct transcriptional regulation.
JDP2 collaborates with c-Myc to initiate T-ALL in the zebrafish
Our data in cell lines convincingly indicate a role for JDP2 in 
maintaining tumor cell survival, but its ability to initiate T-ALL 
remained in question. In zebrafish, the murine c-Myc oncogene 
initiates a highly aggressive T-ALL when expressed from the 
zebrafish rag2 promoter (Langenau et al., 2003). In this model, 
transgenes form concatemers before genomic co-integration, 
enabling mosaic expression of up to three transgenes injected 
simultaneously into recently fertilized one-cell zebrafish 
embryos (Langenau et al., 2008). This allows putative oncogenes 
to be rapidly assessed for their ability to collaborate with c-Myc 
in transforming early thymocytes. We thus coinjected single-cell 
embryos with rag2: mCherry, rag2: mCherry/ rag2: Myc, or rag2: 
mCherry/ rag2: Myc/ rag2: jdp2 and monitored the fish by fluo-
rescent microscopy for tumor onset (Fig. 5 A). Coexpression of 
jdp2 with murine c-Myc led to a marked increase in tumor pen-
etrance, with 80% of fish exhibiting T-ALL at 120 d, compared 
with 40% when c-Myc was expressed alone (P = 0.001; Fig. 5 B). 
These data are consistent with the high incidence of activating 
Jdp2 viral integrations that are selected based on their ability to 
accelerate the onset of T-ALL in mice with a c-Myc transgenic 
background (Stewart et al., 2007).
JDP2 can initiate T-ALL in zebrafish lacking ectopic 
c-Myc expression
Next, we asked whether jdp2 overexpression was sufficient to 
initiate tumorigenesis in the zebrafish without the requirement 
for ectopic coexpression of c-Myc. For these experiments, we cre-
ated a stable founder zebrafish line expressing rag2: mCherry/ 
rag2: jdp2 (termed here Tg(rag2: jdp2)). During normal matura-
tion of the thymus in zebrafish, the size of the organ peaks at 10 
wk of age, followed by progressive thymic involution. Similar to 
other species such as rodents and humans, we noted consider-
able variations in thymic size between individual zebrafish of 
the same age (Paton and Goodall, 1904; Nasseri and Eftekhari, 
2010). However, in transgenic fish stably expressing jdp2, there 
was a marked increase in thymic size compared with Tg(rag2: 
mCherry) fish, which was most apparent at 8–10 wk of age and 
was associated with a delay in thymic involution when monitored 
patients treated on the COG P9404 trial, together with the mutational status of recurrently mutated genes. Yellow boxes denote wild-type genes, and black 
boxes, the presence of a genetic lesion. (E) Kaplan–Meier curves showing overall survival for pediatric T-ALL patients treated on the COG P9404 trial, stratified 
by JDP2 and ETP status. Patients were considered JDP2-positive using a probe presence score of ≥30; survival differences were calculated using the log-rank 
test. (F) JDP2 gene expression in 21 human T-ALL cell lines as determined by Affymetrix gene expression array. Lower panel shows JDP2 protein expression in 
a selection of T-ALL cell lines as determined by Western blot analysis. Representative Western blot from two independent experiments is shown.
Mansour et al. 
JDP2 oncogene in T-ALL
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20170484
1933
Figure 2. Human T-ALL lines are highly dependent on JDP2 for cell growth. (A) Cell growth kinetics in Loucy and KOPT-K1 T-ALL cells, stably expressing a 
doxycycline-inducible JDP2 shRNA. Corresponding Western blots showing JDP2 protein expression with or without doxycycline. Representative data from three 
separate experiments are shown. (B) JDP2 depletion induces apoptosis in human T-ALL cell lines as determined by flow cytometric evaluation for TUN EL and 
PI in Loucy (left) and KOPT-K1 (right) cells stably expressing a doxycycline-inducible JDP2 shRNA, with and without doxycycline treatment for 24 h. Data were 
verified in two independent experiments. (C) Time course showing the kinetics of JDP2 depletion by Western blot analysis, and apoptosis induction measured 
by flow cytometry for TUN EL, in doxycycline-inducible JDP2 shRNA Loucy (left) and KOPT-K1 (right) cells after the addition of doxycycline. Representative 
Western blot from two independent experiments is shown. Data points represent the mean ± standard error of the mean.
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over 14 wk, consistent with hyperplasia (Fig. 5, C and D; and Fig. 
S5 A). Although thymic fluorescence was undetectable in all 
Tg(rag2: mCherry) fish at 40 wk of age (n = 24), it was retained in 
all Tg(rag2: jdp2) fish (n = 15; Fig. 5 E). This phenotype is reminis-
cent of what we had previously observed in transgenic Tg(rag2: 
bcl2) fish, suggesting that jdp2 may play a role in mediating 
anti-apoptotic signaling (Feng et al., 2010).
Strikingly, beginning at 40 wk of age, 8 of 15 Tg(rag2: jdp2) 
fish (53%) developed tumors (Fig. 5 F). Leukemic transformation 
was indicated by infiltration of mCherry-positive cells beyond 
the thymus, that progressed to involve the kidney marrow and 
ultimately the entire fish, similar to previous observations in 
our rag2: Myc transgenic fish lines (Langenau et al., 2003). In 
Tg(rag2: jdp2) fish, the kidney marrow was massively infiltrated 
with blast cells with a monomorphic appearance and high nucle-
ar-to-cytoplasmic ratio, whereas blast cells were readily detect-
able on peripheral blood smears, indicative of leukemia (Fig. 6 A). 
Consistent with a T cell phenotype, qPCR from purified tumor 
cells showed high cd3 mRNA expression at levels comparable 
to those in Tg(rag2: Myc) transgenic tumors and normal thymo-
cytes (Fig. S5 B). Furthermore, the results of RNA-sequencing 
(RNA-seq) of sorted tumor cells from Tg(rag2: jdp2) fish showed 
expression of bcl11b, gata3, lmo2, cd8, il7r, and rag2, consistent 
with a diagnosis of T-ALL. Given the ability of JDP2 to regulate 
MCL1 expression in human cells, we analyzed mcl1a expression 
in zebrafish tumors. As shown in Fig. 6 C, mcl1a expression was 
approximately twofold higher in Tg(rag2: jdp2) compared with 
Tg(rag2: Myc) tumor cells or normal thymocytes (mean expres-
sion, 641 vs. 315 and 356 reads per kilobase of exon per million 
fragments mapped, P = 0.003 and P = 0.01, respectively Fig. 6 C), 
consistent with our findings of direct regulation of MCL1 by JDP2 
in human cells.
Tg(rag2: jdp2) tumors are transplantable into 
secondary recipients
To test whether tumors from Tg(rag2: jdp2) zebrafish har-
bor leukemia-initiating cells, we exploited a recently devel-
oped immune-compromised zebrafish line with a rag2E450fs 
Figure 3. JDP2 occupies both promoters and 
enhancers and can both activate and repress tar-
get genes. (A) The preferred binding sequence for 
JDP2 is the palindromic TRE motif as calculated using 
Analysis of Motif Enrichment from the MEME suite. 
The adjusted P value is shown. Mean JDP2 occupancy 
from the TSS to TES at gene bodies, as analyzed from 
genome-wide binding by ChIP-seq in Loucy cells. The 
y axis shows ChIP-seq read concentration normal-
ized to number of base pairs in the given region type. 
Right: Relative genome-wide occupancy of JDP2 
at gene promoters (green), at enhancers (red), and 
within the gene body (white). (B) Volcano plot show-
ing log2 fold change (FC) in gene expression 20 h after 
JDP2 knockdown in Loucy (left) and KOPT-K1 (right) 
cells stably expressing a doxycycline-inducible JDP2 
shRNA. The y axis shows adjusted P value. Genes 
represented in blue are significantly down-regu-
lated, those in red are significantly up-regulated, and 
those in black are not differentially expressed. RNA-
seq was performed in biological triplicate. (C) Graph 
illustrating the number of genes in Loucy cells that 
are differentially expressed (by RNA-seq) after JDP2 
knockdown and either bound by JDP2 (by ChIP-seq; 
direct target genes) or not bound by JDP2 (genes reg-
ulated indirectly after JDP2 knockdown).
Mansour et al. 
JDP2 oncogene in T-ALL
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20170484
1935
Figure 4. JDP2 prevents apoptosis by directly regulating MCL1. (A) Waterfall plot showing genes most closely correlated with JDP2, using Pearson cor-
relation analysis of gene expression data from 165 T-ALL patients from the MILE study (Haferlach et al., 2010). The y axis represents the Pearson correlation 
coefficient (R value) positively and negatively associated with JDP2 expression, adjusted for multiple testing using the false discovery rate, and P < 0.001. Genes 
are distributed across the x-axis, with position of MCL1 highlighted. (B) Direct correlation between JDP2 and MCL1, from Fig. 4 A, is shown in detail together 
with line of best fit. (C) ChIP-seq tracks for JDP2 and H3K27ac at the MCL1 locus in Loucy cells. (D) Relative JDP2, MCL1, and BCL2 mRNA levels over time after 
the addition of doxycycline to Loucy cells (left) and KOPT-K1 cells (right) stably expressing doxycycline-inducible JDP2 shRNA#2. qPCR experiments were per-
formed in triplicate and verified in two independent experiments. (E) Western blots showing kinetics of MCL1 depletion and PARP1 cleavage after the addition 
of doxycycline in Loucy and KOPT-K1 cells expressing a doxycycline-inducible JDP2 shRNA. Representative Western blot from two separate experiments is 
shown. (F) Doxycycline-inducible JDP2 shRNA expressing Loucy and KOPT-K1 cells were stably transduced to express either GFP (control) or MCL1, and then 
treated with or without doxycycline, and viable cell number was measured by Cell Titer Glo at 24 h. Bottom: Western blots showing MCL1 and JDP2 expression 
in the transduced cell lines. P values were calculated using two-tailed Student’s t test applied to triplicate experiments performed twice. Data points represent 
the mean ± standard error of the mean.
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Figure 5. Jdp2collaborates with Myc and can initiate T-ALL in a zebrafish model. (A) Schematic showing the coinjection strategy used to identify Myc 
collaborating genes in first generation mosaic transgenic zebrafish. (B) Kaplan–Meier curves showing tumor onset in first-generation mosaic zebrafish coin-
jected with constructs expressing rag2: Myc + rag2: jdp2 + rag2: mCherry (red line), versus rag2: Myc + rag2: mCherry versus (black line), versus rag2: mCherry 
alone (blue line). (C) Representative fluorescent images of thymuses from 8-wk-old stable transgenic zebrafish expressing Tg(rag2: mCherry) and Tg(rag2: jdp2). 
Bars, 1 mm. (D) Quantification of thymus size from Tg(rag2: mCherry) and Tg(rag2: jdp2) assessed by fluorescent microscopy biweekly from 4 to 14 wk of age. 
To account for intervariation in fish size, thymus size was normalized to head size. * P<0.05; ** P<0.005; *** P<0.0005. Data points represent the mean ± 
standard error of the mean. (E) Representative fluorescent microscopy images from a 40-wk-old Tg(rag2: mCherry), and three Tg(rag2: jdp2) zebrafish. Bars, 1 
mm. (F) Kaplan–Meier curves showing tumor onset in stable Mendelian transgenic zebrafish expressing Tg(rag2: mCherry; red line) and Tg(rag2: jdp2; blue line).
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Figure 6. Jdp2initiates a transplantable T-ALL when expressed from the rag2 promoter. (A) Hematoxylin and eosin staining of peripheral blood and kidney 
marrow smears from 11-mo-old Tg(rag2: mCherry) and Tg(rag2: jdp2) fish. Note that red blood cells are nucleated in normal zebrafish. Black arrow identifies 
a mature myeloid cell, and red arrows, circulating blast cells. Bars, 10 µm. (B) Heatmap showing expression of selected genes from FACS-purified cells from 
normal thymocytes from Tg(rag2: mCherry) zebrafish (each column n = 10 pooled), and tumors from Tg(rag2: jdp2) and Tg(rag2: Myc) fish (each column represents 
an individual fish), as determined by RNA-seq. RPKM, reads per kilobase of exon per million fragments mapped. (C) mcl1a expression by RNA-seq analysis of 
FACS-purified fluorescent cells. For the Tg(rag2: Myc) and Tg(rag2: jdp2) genotypes, each data point represents an individual fish, whereas for normal thymus, 
each point represents pooled cells harvested from 10 Tg(rag2: mCherry) animals. (D) Tumor cells were harvested from Tg(rag2: jdp2) fish and injected into the 
circulation of 2-d-old recipient fish homozygous for a hypomorphic rag2 allele (E450fs). Two representative embryos are shown, and findings were validated in 
two independent experiments. Bars, 0.1 mm. (E) Tumor cells harvested from Tg(rag2: jdp2) fish were injected into the peritoneum of adult homozygous rag2E450fs 
fish. Recipients were monitored by fluorescence imaging. Findings were validated in three independent experiments. Bars, 0.5 mm.
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hypomorphic allele, which is permissive of adoptive transfer of 
allogeneic zebrafish cells (Tang et al., 2014). When tumor cells 
harvested from Tg(rag2: jdp2) fish were injected into the circula-
tion of 2-d-old rag2E450fs (Casper) mutant embryos, they rapidly 
migrated to and engrafted in the thymus of recipient larvae, con-
sistent with their thymic origin (Fig. 6 D). Within 7 d of implanta-
tion, tumors had disseminated throughout the larvae, indicating 
that donor cells had proliferated in the recipient animals, even-
tually leading to death of the animals (Fig. 6 D). This finding was 
corroborated by the rapid tumor expansion visible when Tg(rag2: 
jdp2) tumors were injected into the peritoneum of adult rag2E450fs 
mutant fish (Fig. 6 E).
Tg(rag2: jdp2) thymocytes are resistant to glucocorticoids (GCs)
GCs form the backbone of most chemotherapy regimens for 
adult and pediatric T-ALL, and early steroid response has proven 
to be an important prognostic marker (Aricò et al., 1995). Fur-
thermore, overexpression of MCL1 has been identified as a key 
regulator of steroid resistance in lymphoid malignancy, through 
its ability to sequester GC-induced BIM (Wei et al., 2006). How-
ever, examining GC responses in vitro has been challenging, as 
unlike the majority of GC-resistant primary T-ALL cases, T-ALL 
cell lines frequently have mutations or down-regulation of GC 
receptors (Geley et al., 1996). We previously demonstrated that 
the zebrafish thymus undergoes rapid apoptosis after the addi-
tion of dexamethasone to the fish water (Langenau et al., 2004). 
Because of the small size of zebrafish larvae and the ability to 
accurately quantify thymic size through fluorescent microscopy, 
this transgenic zebrafish line seemed an ideal model with which 
to test GC resistance in vivo.
We thus exposed 5-d-old zebrafish to dexamethasone and 
monitored thymic size. As expected, dexamethasone led to a 
marked reduction in thymic fluorescence over 3 d of exposure in 
Tg(rag2: mCherry) reporter fish (mean thymic fluorescent inten-
sity 6.6% of vehicle-treated controls) and was also highly effective 
in Tg(rag2: Myc) transgenic fish (mean thymic fluorescent inten-
sity 7.9% of vehicle-treated controls; Fig. 7 A). However, Tg(rag2: 
jdp2) zebrafish had significantly higher amounts of residual 
thymic tissue after exposure to dexamethasone (mean thymic 
fluorescent intensity 14.9% of vehicle-treated controls, P = 0.007 
and P = 0.02 vs. rag2: mCherry and rag2: Myc, respectively; Fig. 7, 
A and B). Fish transgenic for both Tg(rag2: Myc) and Tg(rag2: 
jdp2) exhibited the most striking GC resistance (mean thymic 
fluorescent intensity 33.0% of vehicle-treated control fish; P < 
0.0001 compared with the response of rag2: Myc). These findings 
are consistent with our observation that JDP2 directly regulates 
MCL1, which is a known mediator of GC resistance (Wei et al., 
2006), thus implicating JDP2-up-regulated MCL1 expression as 
at least one of the causes of the inferior outcome identified in 
patients with JDP2 overexpression.
Discussion
Insertional mutagenesis screens have been highly fruitful in 
identifying novel oncogenes that subsequently prove to be 
directly relevant to human disease. For instance, EVI1, HOXA, 
and MEIS1 were first identified by their overexpression resulting 
from adjacent recurrent integration sites in murine insertional 
mutagenesis models of AML, before appreciation of their promi-
nent roles in the human disease (Morishita et al., 1988; Nakamura 
et al., 1996). Similarly, MYC and NOT CH-1, the most commonly 
dysregulated oncogenes in human T-ALL, are both targets of ret-
roviral activation in murine insertional models of this disease 
(Girard et al., 1996; Hoemann et al., 2000; Weng et al., 2004). 
Interpretation of these assays assumes that integration of viral 
sequences throughout the genome is random, and that the ear-
liest leukemias arise from cells where the viral LTR has resulted 
in dysregulation of a nearby tumor suppressor or oncogene. A 
pertinent example of this phenomenon in humans can be found 
in the development of T-ALL in severe combined immunodefi-
ciency patients who received retrovirally transduced, gene-cor-
rected autologous hematopoietic stem cells, where the viral LTR 
integrated into the vicinity of the LMO2 gene (Hacein-Bey-Abina 
et al., 2003, 2008; Howe et al., 2008).
Our data strongly support both viral and transposase-based 
insertional mutagenesis models that implicate JDP2 as a T-ALL 
oncogene. One proposed mechanism by which the JDP2 protein 
exerts its oncogenicity in this setting is through suppression of 
TP53, given that T-ALLs arising on a TP53 heterozygous back-
ground have a particularly high frequency of insertions at the 
Jdp2 promoter (van der Weyden et al., 2013). Although this mech-
anism is intriguing, it is unlikely to be responsible for the ability 
of jdp2 to transform thymocytes in our zebrafish model, where 
loss of tp53 neither induces T-ALL nor collaborates with Myc in 
tumorigenesis (Gutierrez et al., 2014). jdp2 thus represents one 
of only a few select oncogenes (including Myc, Notch, and Myr-
AKT) capable of initiating T-ALL in the zebrafish; the long dis-
ease latency and incomplete penetrance in our model suggests 
that as-yet undiscovered secondary mutations are likely to be 
involved in transformation (Langenau et al., 2003; Gutierrez et 
al., 2011; Blackburn et al., 2012, 2014).
Although the majority of studies support a repressive role for 
JDP2 through its ability to recruit histone deacetylases and its 
interaction with histones and the PRC2 complex, our ChIP-seq 
data suggest it can also have a role as a transcription activator 
in T-ALL cells. Unfortunately, we were unsuccessful in study-
ing histone modifications after JDP2 knockdown, presumably 
because of nuclear fragmentation of cells undergoing apoptosis. 
Interestingly, a previous study has shown that JDP2 can strongly 
enhance transcription from promoters containing TREs, but not 
from those containing CREs, consistent with the preferential 
binding of JDP2 to TREs at active genes identified in our ChIP-
seq experiments (Weidenfeld-Baranboim et al., 2008). One other 
factor that could potentially impact the transcriptional activity 
of JDP2 is that approximately half of ETP-ALL cases have inac-
tivating mutations of members of the PRC2 complex (Zhang et 
al., 2012). Loucy cells, for instance, lack detectable EZH2 mRNA 
expression, but whether this influences the role of JDP2 as a 
repressor or activator will require further study.
The most striking phenotype in vitro was a dependency 
of human T-ALL–derived cell lines on JDP2 for their survival. 
Mechanistically, JDP2 regulates prosurvival signaling through 
direct transcriptional regulation of the anti-apoptotic gene 
MCL1; indeed, programmed expression of MCL1 was sufficient 
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to rescue the apoptotic effects of JDP2 depletion. We and others 
have recently shown that ETP-ALL cells depend on BCL2 for their 
survival (Anderson et al., 2014; Chonghaile et al., 2014; Peirs et 
al., 2014). Given that BCL2 and MCL1 are able to bind and seques-
ter the same BH3-only proteins, BIM and BID, our current data 
suggest that Loucy cells are “primed” for apoptotic death through 
this pathway, such that inhibition of either BCL2 or MCL1 is suf-
ficient to trigger apoptosis. In support of this concept, previous 
studies have shown that MCL1 depletion alone dramatically 
impairs the viability of Loucy cells (Ariës et al., 2013).
Many ALL cell lines show down-regulation or mutations of 
the GC receptor, features that are only rarely found in primary 
T-ALL samples, limiting what can be learned from studying GC 
sensitivity of T-ALL cell lines in vitro (Geley et al., 1996). This 
was one of the reasons we chose to study GC responses in our 
zebrafish model, where the ease in imaging the fluorescently 
labeled thymus in zebrafish embryos, and its exquisite sensitiv-
ity to dexamethasone, makes it an attractive model for studying 
GC responses in vivo. We show that the premalignant thymus in 
Tg(rag2: jdp2) transgenic zebrafish is resistant to GC treatment. 
Similar to our findings in T-ALL cell lines and patients, zebrafish 
mcl1 expression levels in thymocytes from Tg(rag2: jdp2) were 
approximately twice those measured in wild-type or Tg(rag2: 
Myc) fish. In light of MCL1 as an important mediator of GC resis-
tance in lymphoid cells (Wei et al., 2006), these observations pro-
vide a potential mechanistic link between JDP2 overexpression, 
GC resistance, and inferior survival in patients with T-ALL. We 
have shown that JDP2 is preferentially up-regulated in ETP-ALL 
Figure 7. Thymuses of Tg(rag2: jdp2) fish are resistant to 
dexamethasone. (A) Representative fluorescent images of thy-
muses from 8-d-old stable transgenic zebrafish larvae exposed 
to dexamethasone (25 µg/ml) or DMSO control, from day 5 post-
fertilization (dpf). Bar, 0.1 mm. (B) Quantification of thymic flu-
orescence in 8-d-old stable transgenic zebrafish larvae exposed 
to 25 µg/ml dexamethasone or DMSO control from 5 dpf. Values 
are expressed as a percentage of thymic fluorescence in DMSO 
control treated zebrafish, and P values were calculated using 
two-tailed Student’s t test. Findings were validated in three 
independent experiments.
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(Fig.  1, C and D), and support for increased GC resistance in 
human ETP-ALL is provided by recent studies in human T-ALL 
patient-derived tumor graft models, in which Delgado-Martin 
et al. (2017) demonstrated that cells from ETP T-ALL models are 
intrinsically more resistant to GCs than are cells from non-ETP 
T-ALLs. Given that bZIP proteins such as JDP2 are extremely 
challenging to target directly, our data suggest that inhibiting 
its downstream effector MCL1 would be a rationale alternative 
approach in patients with JDP2 overexpression, once specific and 
potent MCL1 inhibitors become available for clinical use.
Materials and methods
Cell lines
The identity of T-ALL cell lines used in this study was verified 
by short tandem repeat analysis using the PowerPlex 1.2 system 
(Promega) in January 2013. T-ALL cells were maintained in RPMI-
1640 supplemented with 10% FBS, l-glutamine, and penicillin/
streptomycin. HEK-293T cells were recently obtained from Amer-
ican Type Culture Collection and maintained in DMEM supple-
mented with 10% FBS, l-glutamine, and penicillin/streptomycin.
shRNA knockdown experiments in T-ALL cell lines
pLKO.1-puromycin lentiviral vectors expressing shRNAs tar-
geting JDP2 or control (luciferase and GFP) were obtained from 
the RNAi Consortium of the Broad Institute. JDP2 shRNA#1 
equates to clone TRCN0000019001 (targeting 5′-ACT CAT GAA 
CGC AGA GCT GAA-3′), and JDP2 shRNA#2 equates to clone 
TRCN0000019002 (targeting 5′-CGA GTC AGA AGG CAA CCC 
ACT-3′). Production of lentivirus and viral transductions was 
performed as previously described (Sanda et al., 2012). To cre-
ate doxycycline-inducible JDP2 knockdown KOPT-K1 and Loucy 
cells, JDP2shRNA#2 oligonucleotides were annealed and cloned 
into the AgeI/EcoRI sites of pLKO1-Tet-on (upper, 5′-CCG GCG 
AGT CAG AAG GCA ACC CAC TCT CGA GAG TGG GTT GCC TTC TGA 
CTC GTT TTT-3′; lower, 5′-AAT TAA AAA CGA GTC AGA AGG CAA 
CCC ACT CTC GAG AGT GGG TTG CCT TCT GAC TCG-3′). KOPT-K1 
and Loucy cells were transduced with lentiviral supernatants, 
selected by puromycin, and single-cell cloned by limiting dilu-
tion. Single-cell clones were expanded and assessed for shRNA 
inducibility by qPCR and Western blotting for JDP2, 24 h after 
the addition of doxycycline. To generate a retrovirus vector 
encoding a wobble mutant JDP2 (JDP2w2, where JDP2w2 refers 
to JDP2 cDNA containing silent/wobble mutations (under-
lined) in the target site of shRNA#2, 5′-CGAATCGGAGGGTA-
ATCCA CT-3′), human JDP2 cDNA was amplified by PCR using 
forward primer, 5′-TTG GGA TCC GCC ACC ATG ATG CCT GGG CAG 
ATC CC-3′, and reverse primer, 5′-TAT AGT CGA CTC ACT TCT 
TCT CGA GCT GCT CGA GCA GTG GAT TAC CCT CCG ATT CGG GGGT-
3′. The PCR products were cut by BamHI and SalI and cloned 
into MSCV-IRES-GFP vector between BamHI and XhoI sites. 
For rescue experiments, KOPT-K1 cells were stably transduced 
with MSCV-IRES-GFP or MSCV-JDP2w2-IRES-GFP, sorted for 
GFP expression by FACS, and subjected to knockdown exper-
iments with pLKO1-JDP2sh#2-puro vector. Cell growth assays 
were performed in 96-well plate format, and cell number was 
assessed at 72  h by Cell Titer Glo (Promega). The retroviral 
vector encoding MCL1 was generated as previously described 
(Akahane et al., 2016).
Apoptosis assays
TUN EL assay and propidium iodide (PI) staining were performed 
using the ApopTag Fluorescein Direct In Situ Apoptosis Detection 
Kit (EMD Millipore) according to the manufacturer’s recommen-
dation. Briefly, 2 × 106 cells of each treated sample were fixed 
with 1% paraformaldehyde in PBS for 15 min on ice, washed in 
PBS, and incubated with 70% ethanol at −20°C overnight. The 
cells were then washed and incubated with DNA labeling solu-
tion containing TdT and BrdU triphosphates for 4 h at 37°C. The 
cells were washed and incubated in the staining buffer contain-
ing an Alexa Fluor 488 dye–labeled anti-BrdU antibody for 30 
min at room temperature, and a mixture of PI/RNase was added. 
After 30-min incubation at room temperature, TUN EL positiv-
ity and cell cycle distribution were analyzed by FAC SCalibur 
(BD Biosciences). Annexin V and PI double staining was also 
used for detecting apoptosis. 2 × 105 cells of each treated sample 
were washed with PBS, incubated in staining buffer containing 
FITC-conjugated anti–annexin V antibody and PI (MBL Interna-
tional), and then analyzed by FAC SCalibur.
T-ALL patient samples
Gene expression data were analyzed from published Affymetrix 
U133 Plus 2.0 arrays from pediatric patients treated on the COG 
P9404 trial and from HumanHT-12 v4 Expression BeadChip (Illu-
mina) from 53 adult T-ALL patients treated on the E2993 ECOG 
trial (Gutierrez et al., 2010; Van Vlierberghe et al., 2013). qPCR 
for JDP2 was performed from 34 diagnostic adult T-ALL cases 
from the UKA LL14 trial. Informed consent was obtained from 
all patients according to the Declaration of Helsinki, and the 
trial was approved by the West London Research Ethics Coun-
cil (09/H0711/90).
Normal thymic subsets
Thymuses were obtained as surgical tissue discards from chil-
dren aged 7 wk to 3 yr undergoing cardiac surgery at the Eras-
mus MC Rotterdam, with informed consent from the parents. 
The children did not have immunological abnormalities. Thy-
mocytes were isolated by cutting the thymic lobes into small 
pieces and squeezing them through a metal mesh, then stored 
in liquid nitrogen. Thymocytes from five donors were used 
to reduce intersample variation. After thawing, pooling, and 
Ficoll density separation, thymocytes were labeled with fluo-
rochrome-conjugated monoclonal antibodies. For the isolation 
of CD34+CD1a− and CD34+CD1a+ thymocytes, CD34+ progenitor 
cells were prepurified by AUT OMA CS (Miltenyi Biotec) using 
the CD34 microbeads kit UltraPure (Miltenyi Biotec) before 
FACS sorting. The following monoclonal human antibodies 
were used: CD1a-PE (HI149), CD3-APC (SK7), CD4-Pacific blue 
(RPA-T4), CD8-FITC (SK1), CD13-PE (L138), CD16-PE (Leu11c), 
CD19-PE (4G7), CD33-PE (P67.6), CD34-APC (581), CD34-PE 
(8G12), and CD56-PE (MY31; all BD Bioscience). Cell sorting 
was performed on a FAC SAria II cell sorter (BD Biosciences). All 
populations were directly sorted as indicated by their marker 
expression (Dik et al., 2005).
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RNA extraction and cDNA and expression analysis
mRNA was extracted using the RNeasy Mini Kit (Qiagen). Puri-
fied RNA was reverse-transcribed with the Superscript III RT kit 
(Invitrogen). qPCR was performed with the Applied Biosystems 
ViiA 7 using gene-specific primers and SYBR Green PCR Master 
Mix (Roche). Primer sequences for qPCR were as follows: human 
JDP2-F 5′-ACG GAG TTT CTG CAG CGG-3′; human JDP2-R 5′-CAG 
CAT CAG GAT GAG CTGC-3′; human β-actin-F 5′-AGA GCT ACG 
AGC TGC CTG AC-3′; human β-actin-R AGC ACT GTG TTG GCG TAC 
AG-3′; human GAP DH 5′-TGC ACC ACC AAC TGC TTA GC-3′; human 
GAP DH 5′-GGC ATG GAC TGT GGT CAT GAG-3′; human MCL1-F 
5′-GGA CAA AAC GGG ACT GGC TA-3′; and human MCL1-R 5′-TGC 
CAA ACC AGC TCC TAC TC-3′.
Western blots and antibodies
Whole cell lysates were prepared in RIPA buffer. For JDP2 West-
ern blots, nuclear fraction protein was prepared using a Nuclear 
Extract Kit (Active Motif). Protein concentration was quantified 
with a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). 
Equivalent amounts of protein were diluted in the Laemmli sam-
ple buffer (Bio-Rad Laboratories) and separated by SDS-PAGE. 
Proteins were transferred to PVDF membranes (Millipore) and 
subjected to immune blot analysis with specific antibodies for 
JDP2 (ab40916; Abcam), BCL2 (4223S; Cell Signaling Technol-
ogy), BCL-XL (2764; Cell Signaling Technology), MCL1 (5453; 
Cell Signaling Technology), PARP1 (9542P; Cell Signaling Tech-
nology), cleaved caspase 3 (9664S; Cell Signaling Technology), 
and β-actin (4967S; Cell Signaling Technology). All primary anti-
bodies were diluted at 1:2,000 in 5% milk in PBST (0.5% Tween-
20 in PBS), except for β-actin, which was diluted to 1:5,000 in 
5% milk in PBST.
ChIP-seq experiments
ChIP coupled with massively parallel DNA sequencing (ChIP-
seq) was performed as previously described (Lee et al., 2006; 
Marson et al., 2008; Mansour et al., 2014). Antibodies used for 
ChIP were anti-JDP2 (sc-23456X; Santa Cruz Biotechnology) 
and anti-H3K27ac (ab4729; Abcam). For each ChIP, 10 µg anti-
body was added to 3 ml of sonicated nuclear extract. Illumina 
sequencing and library construction methods were previously 
described (Marson et al., 2008). Reads were aligned to build hg19 
of the human genome using Bowtie 1.0.1 with parameters –best 
–k 2 –m 2–sam –l 40 (Langmead et al., 2009). For visualization 
in the UCSC genome browser (Kent et al., 2002), WIG files were 
created from aligned ChIP-Seq read positions using MACS with 
parameters –w –S –space = 50 –nomodel –shiftsize = 200 to arti-
ficially extend reads to be 200 bp and calculate their density in 
50-bp bins (Zhang et al., 2008). Read counts in 50-bp bins were 
then normalized to the millions of mapped reads, giving reads 
per million values.
ChIP-seq processing
Regions enriched in ChIP-seq signal, termed islands, were iden-
tified using SIC ER with corresponding control and parameters 
–t 1 (reads with unique positions) –w 200 (window size 200 bp) 
–g 200 (gap size 200 bp) –i 200 (read shift 200 bp) –t 0.74 (map-
pable genome) –p 1e-3 (island significance threshold; Zang et 
al., 2009). We used SIC ER over other peak callers to capture the 
observed range in type/breadth of islands.
Read distribution in regions
To determine the preference of JDP2 to bind different types of 
regions, we counted the reads from JDP2 ChIP-Seq in promot-
ers (TSS ± 1,000 bp), gene bodies (TSS + 1,000 to transcription 
end site [TES]), and enhancers (H3K27ac peaks). Only genes 
greater than 1,000 bp were considered. Reads were first counted 
in promoters; remaining reads were counted in bodies; remain-
ing reads were counted in enhancers. Counts were divided by 
the total number of bases in these region types and displayed 
as percentage stacked bar plots. The mean gene-centric profile 
of JDP2 was determined using bamToGFF (https:// github .com/ 
BradnerLab/ pipeline) on three regions. The upstream 2,000 bp 
was divided into 50 equally sized bins; the region TSS to TES was 
divided into 150 equally sized bins; the downstream 2,000 bp was 
divided into 50 equally sized bins. Each BamToGFF produced 
matrices of RPM-normalized ChIP-Seq read counts in these bins 
and used parameters –e 200 –f 0 –r. The mean value in each bin 
was plotted using Matplot. ChIP-Seq signal around individual 
genomic landmarks (promoters, JDP2 islands, and enhancers) 
was calculated using BamToGFF and is displayed in Fig. 3 A. Pro-
moters (TSS ± 5,000 bp), JDP2 islands (10,000 bp centered on 
the middle of JDP2 islands from SIC ER), and enhancers (10,000 
bp centered on the middle of H3K27ac islands) were partitioned 
into 50, 50, and 150 bins, respectively. Heatmaps represent the 
RPM-normalized read counts in these bins in each of 37,973 pro-
moters of RefSeq genes or 27,643 H3K27ac islands that do not con-
tact a promoter or 12,649 JDP2 islands. Each region is a row, and 
rows are ordered by the sum of JDP2 signal in that row.
Motif analyses
To calculate the enrichment of JDP2 DNA-binding motifs in JDP2 
islands, we used AME from the MEME suite (McLeay and Bailey, 
2010). Position weight matrices were used to scan the genome 
sequence in the JDP2 islands with parameters –method fisher 
–scoring totalhits to calculate the count enrichment in these 
motifs (Jolma et al., 2013). The corrected P value is reported.
Zebrafish models
Zebrafish maintenance and all animal experimental procedures 
were approved by the Dana-Farber Cancer Institute Institutional 
Animal Care and Use Committee–approved protocol #02-107 and 
Massachusetts General Hospital Subcommittee on Research Ani-
mal Care, under protocol #2011N000127.
Mosaic coinjection experiments
DNA constructs used to generate mosaic transgenic zebrafish 
included rag2: mCherry and rag2: mMyc (encoding murine Myc; 
Langenau et al., 2003; Smith et al., 2010). Zebrafish jdp2b (cor-
responding to ENS DARG00000020133; zgc: 92851) was ampli-
fied from zebrafish cDNA (primer forward: 5′-CAC CAT GAT GCC 
TGG TCA AAT CCC TGA TCC-3′; primer reverse: 5′-TCA GTC TTC 
GCG GGG CTC CAGC-3′), subcloned into pENTR gateway system 
(Life Technologies) and transferred into the rag2 promoter des-
tination vector using LR clonase II (Life Technologies). Plasmids 
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were linearized with NotI or XhoI and purified. Mosaic transgenic 
animals were generated as previously described (Langenau et al., 
2008). 40 ng/µl rag2: mCherry was mixed with 40 ng/µl rag2: 
Myc, and 40 ng/µl rag2: jdp2 was microinjected into one-cell-
stage Tu/AB embryos. Mosaic transgenic animals were monitored 
for T-ALL onset at day 21 and every 7 d thereafter by fluorescent 
microscopy after tricaine anesthesia.
Generation of stable Tg(rag2: jdp2/ rag2: mCherry) zebrafish line
To create a stable Tg(rag2: jdp2/ rag2: mCherry) zebrafish line, 
jdp2b (corresponding to zebrafish ENS DARG00000020133; 
zgc: 92851) was amplified from zebrafish cDNA (primer for-
ward: 5′-TAT AGG ATC CGC CCA AAT CCC TGA TC-3′; primer reverse 
5′-TAT AAT CGA TTC AGC GGG GCT CCA GC-3′), digested by BAM HI 
and ClaI, and cloned into the BAM HI/ClaI sites downstream of 
the zebrafish rag2 promoter in a modified pBluescript vector 
containing flanked recognition sequences for I-SceI meganucle-
ase (Gutierrez et al., 2011). rag2: mCherry and rag2: jdp2 vectors 
were digested by I-SceI and coinjected together into one-cell-
stage AB embryos using a previously described I-SceI coinjec-
tion strategy (Grabher and Wittbrodt, 2008). jdp2b expression 
was quantified by isolating mCherry fluorescent cells by FACS, 
extracting RNA, and performing qPCR with the following prim-
ers: zf-jdp2b-F 5′-TTG CAG CTG CTC GCT GTC-3′; zf-jdp2b-R 5′-GCT 
CCG ACT TCA GCT CCTC-3′; zf-β-actin-F 5′-TAC AAT GAG CTC CGT 
GTT GC-3′; and zf-β-actin-R 5′-ACA TAC ATG GCA GGG GTG TT-3′). 
Tg(rag2: mCherry) and Tg(rag2: jdp2/ rag2: mCherry) zebrafish 
were screened for tumors by fluorescence microscopy every 
2 wk starting from the age of 10 wk. Fluorescence microscopy 
was performed with a Leica M420 microscope equipped with 
an X-Cite 120 Fluorescence Illumination System (EXFO). Kidney 
and peripheral blood smears, as well as MGG staining, were per-
formed as previously described (Gjini et al., 2015).
Imaging and quantification
For in vivo steroid sensitivity testing, 5-dpf larvae were sorted 
for thymic fluorescence, treated with dexamethasone (25 µg/
ml, 0.25% ethanol) or ethanol vehicle alone (0.25%) in standard 
egg water, and imaged by fluorescent and light microscopy. For 
bright-field DIC images, a Zeiss Axio Imager.Z1 compound micro-
scope equipped with an AxioCam HRc was used. For live imaging, 
zebrafish and larvae were anaesthetized using 0.016% tricaine 
(Sigma) and mounted in 4% methylcellulose (Sigma). A Nikon 
SMZ1500 microscope equipped with a Nikon digital sight DS-U1 
camera was used for capturing both bright-field and fluorescent 
images from live zebrafish and larvae. For thymic fluorescence 
quantification, all animals in the same experiments were imaged 
at the same condition, and the acquired fluorescent images were 
quantified in ImageJ (NIH) by measuring the fluorescent-covered 
areas. To account for variation in fish size, the thymic fluorescent 
area was normalized against the bright-field area of the fish head. 
Overlays were created using ImageJ and Adobe Photoshop 7.0.1.
RNA-seq data processing
The RNA-seq data were processed using Tophat and Cufflinks 
package according the RNA-seq experiments protocol (Trapnell 
et al., 2012). First, RNA-seq raw reads were filtered using 
Fastx-toolkit (FAS TX-Toolkit, 2018), the reads with n > 5% or 
with low-quality bases (Q <20) >20% were removed, and the 
remaining low-quality bases (Q <20) were trimmed. The clean 
reads were aligned using Tophat2 (Kim et al., 2013), zebrafish 
genome release version Zv9, and the Ensembl annotated version 
73 was used as the transcript model reference for the alignment 
as well as the isoform quantifications. After alignment, the gene 
and isoform expression levels were produced using Cufflinks 
in fragments per kilobase of transcript per million fragments 
mapped. RNA-seq in Loucy and KOP TK1 cells were aligned to 
the hg19 version of the human reference genome using tophat 
with parameters –library-type fr-firststrand –no-novel-juncs 
and -G set to human RefSeq genes downloaded on July 5, 2017. 
Per-RefSeq-gene expression was calculated using htseq-count 
with parameters -i gene_id –stranded=reverse -f bam -m inter-
section-strict (Anders et al., 2015). Differential expression was 
determined using DESeq2 (Love et al., 2014). Genes were con-
sidered significantly differentially expressed if they had a 
DESeq2-normalized log2 fold-change greater or less than 1 (2 
linear fold) and a DESeq2 adjusted P value < 0.05.
Datasets, accession numbers, and data analyses
The following GEO gene expression datasets were analyzed: 
GSE14618 (COG P9404 trial), GSE26713 (COA LL/DCOG trials), 
GSE42328 (ECOG2993), and GSE13159 (MILE study; Gutierrez 
et al., 2010; Haferlach et al., 2010; Homminga et al., 2011; Van 
Vlierberghe et al., 2013). Loucy input control and H3K27ac ChIP-
seq are available under GSM2311760 and GSM2037788, respec-
tively. JDP2 ChIP-seq and RNA-seq datasets are available under 
GSE115465 and GSE115464, respectively. 
Statistical analysis
Differences in overall survival for patients on the COG P9404 
trial, and differences in time to tumor formation in zebrafish, 
were assessed by the log-rank test, and time-to-event distribu-
tions were estimated and plotted via the Kaplan–Meier method in 
Prism. For survival data, patients were determined as JDP2 posi-
tive if their expression value was in the top quartile. Our use of the 
top quartile to define T-ALLs with aberrant JDP2 expression lev-
els is consistent with data from qPCR showing that the top quar-
tile of patients overexpress JDP2 compared with the ISP thymic 
subset (Fig. 1 B), which expresses the highest JDP2 levels among 
all normal thymic subsets. Differences in JDP2 mRNA expression 
between ETP versus non-ETP subgroups were calculated using 
the Student’s t test. Correlation analysis was performed using 
the R2 database (R2: Genomics Analysis and Visualization Plat-
form; http:// r2 .amc .nl) from 165 T-ALL patients recruited onto 
the MILE study (Haferlach et al., 2010), using JDP2 Affymetrix 
probe 226267_at and a P value cutoff of <0.001 adjusted for mul-
tiple testing using the false discovery rate. Waterfall plots were 
generated in Excel with R value cutoffs of ±0.3.
Online supplemental material
Fig. S1 shows cell growth kinetics after lentivirus-mediated 
shRNA depletion of JDP2 with two independent shRNAs in 
Loucy cells and KOPT-K1 T-ALL cells. Fig. S2 shows specificity 
of selected JDP2 shRNAs through lack of toxicity across a panel 
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of cell lines, lack of effect in non-JDP2-expressing DND-41 cells, 
and rescue of cell growth with JDP2 reexpression. Fig. S3 shows 
that JDP2 depletion initiates apoptosis as determined by flow 
cytometry for annexin V and Western blotting for PARP1 and 
caspase-3 cleavage. Fig. S4 shows positive correlation of JDP2 
and MCL1 expression in different T-ALL patient cohorts. Fig. S5 
shows delayed involution of thymus in sections from 23-wk-old 
Tg(rag2: jdp2) zebrafish, as well as expression of CD3 by qPCR. 
Table S1 shows correlation analysis of genes most negatively and 
positively associated with JDP2 expression in T-ALL patients 
from the MILE study.
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